Sign in
Taking people in ItalyPhase 2

Dapagliflozin for people with advanced liver cirrhosis whose liver is failing

Tests the safety of dapagliflozin in adults with decompensated liver cirrhosis.

Key facts

Who runs it
Azienda Ospedale-Universita Padova
Where
Bologna, Milan, and Padova, ItalySee the 3 sites
Registry title
Dapagliflozin in the treatment of decompensated liver cirrhosis: phase IIb randomised, controlled clinical trial
Status
Recruiting
Phase
Phase 2
People taking part
110 people, planned
Started
28 Jul 2025
Planned end
30 May 2026
Type of study
Interventional
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis that has worsened (decompensated) in the past 12 months. It compares dapagliflozin with standard medical therapy.

Age
18 to 85 years
Sex
All sexes can join.
Disease stage
Liver cirrhosis with decompensation in the past 12 months: overt hepatic encephalopathy (brain confusion from liver failure), clinically significant ascites (fluid in the belly), or bleeding from esophageal varices.
Earlier treatment
People cannot join if they are taking SGLT2 inhibitors, have a TIPS, are on or finished HCV direct antiviral treatment < 6 months before, or started HBV nucleoside/nucleotide analogs < 6 months before.
Biomarker or test result
Cirrhosis shown by tissue exam and/or clinical or imaging tests (ultrasonography, CT scan or liver elastography > 15 kPa).

Main reasons for not taking part

  • Acute kidney injury in the 4 weeks before enrolment, or chronic kidney disease with VFG < 30 ml/min/1.73m2
  • Ascites that does not respond to diuretic (water pill) therapy
  • Liver cancer beyond the Milan criteria, or active cancer outside the liver
  • Past solid organ transplant, type 1 diabetes or past diabetic ketoacidosis
  • Pregnancy or breastfeeding, drinking more than 21 alcohol units a week, or BMI < 20 kg/m^2

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age between 18 and 85 years
  • Diagnosis of liver cirrhosis, documented on the basis of histological examination and/or clinical and/or instrumental examinations (ultrasonography, CT scan or liver elastography > 15 kPa)
  • Liver cirrhosis decompensation (overt hepatic encephalopathy, clinically significant ascites, hemorrhage from esophageal varices) developed within the past 12 months

Who cannot take part

  • Active therapy for HCV eradication with Direct Antiviral Agents or terminated < 6 months before
  • Therapy for HBV suppression with nucleoside/nucleotide analogs started < 6 months before
  • Presence of at least one episode of acute kidney injury (AKI) in the 4 weeks prior to enrollment
  • Presence of two or more episodes of urinary tract infection in the 12 months prior to enrollment
  • Presence of >2 episodes of "overt" hepatic encephalopathy in the 12 months prior to enrollment
  • History of prior solid organ transplantation
  • Inclusion in other clinical trials in the month prior to study initiation
  • Ongoing therapy with SGLT2 inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin etc)
  • Diagnosis oftype 1 Diabetes Mellitus and/or previous history of diabetic ketoacidosis
  • Ascites refractory to diuretic therapy according to International Club of Ascites criteria
  • Established hypersensitivity to Dapaglifozin
  • Active extrahepatic malignancy
  • Chronic kidney disease with estimated VFG < 30 ml/min/1.73m2
  • Other known extrahepatic diseases of severe grade (e.g., heart failure NYHA class ≥ 3; COPD GOLD class ≥ 3; psychiatric disorders)
  • Pregnancy or breastfeeding (in the case of women of childbearing age, they will be asked to maintain effective contraception or, alternatively, abstention from sexual intercourse during the observation period)
  • Patient who is a carrier of TIPS
  • Active alcohol consumption greater than 21 weekly alcohol units
  • Body mass index (BMI) < 20 kg/m^2
  • Presence of mental incapacity, complete language barrier, poor social support, or other reasons that, in the opinion of the investigator, may preclude the proper conduct of the study
  • Refusal or inability to sign informed consent and absence of a legal guardian capable of signing consent
  • Hepatocarcinoma outside the Milan criteria (a single nodule<5 cm or multiple nodules [maximum 3], the largest of which ≤3 cm)

This trial is currently available in Italy.

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
  • ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
  • Azienda Ospedale Universita PadovaPadova, ItalyTaking people

About the trial

What the trial wants to find out

The primary objective of the study will be to evaluate the safety of dapagliflozin versus standard medical therapy in patients with decompensated liver cirrhosis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Dapagliflozin in the treatment of decompensated liver cirrhosis: phase IIb randomised, controlled clinical trial
Plain-language title
Dapagliflozin for people with advanced liver cirrhosis whose liver is failingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026